Merus Labs International Inc (MSL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Merus Labs International Inc (MSL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH279902D
  • |
  • Pages: 51
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Merus Labs International Inc (Merus Labs International) formerly Merus Labs Inc, is a specialty pharmaceutical company which offers diversified line of products. Its portfolio encompasses products in various therapeutic areas such as oncology, women's health, thromboembolic diseases, overactive bladder syndrome, cardiovascular, urology, and infectious disease. The company targets the underdeveloped assets and optimizes their returns and also acquires established products for leveraging its expertise and commercial platform in Canada, Europe, and other markets. The company's geographic focus spans North America and Europe. It operates through subsidiaries in Luxembourg, British Columbia, the Netherlands, and the US. Merus Labs International is headquartered in Toronto, Ontario, Canada.

Merus Labs International Inc (MSL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Merus Labs International Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Merus Labs International Inc, Medical Devices Deals, 2011 to YTD 2017 11

Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

Merus Labs International Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 13

Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 14

Merus Labs Acquires Rights to Salagen and Estraderm MX from Novartis Pharma for USD30 Million 15

Merus Labs Acquires Sintrom from Novartis 16

Merus Labs Completes Acquisition Of Prescription Medicine Product From Novartis 17

Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 18

Merus Labs Acquires Canadian Rights Of Vancocin From Iroko International 19

Equity Offering 20

Merus Labs Raises USD21 Million in Private Placement of Shares upon Exercise of Warrants 20

Merus Labs Raises USD20 Million in Private Placement of Subscription Receipts 21

Merus Labs Completes Partial Exercise of Underwriter's Over Allotment Option for Public Offering of Shares for USD63 Million 23

Merus Labs Raises USD9.2 Million in Private Placement of Preferred Shares 24

Merus Labs Raises USD28.7 Million in Public Offering of Shares 25

Merus Labs International Completes Underwriters Exercise Of Full Over-Allotment Option Of Private Placement Of Shares For US$20.7 Million 26

Merus Labs Completes Private Placement Of Shares For US$4.4 Million 27

Merus Labs Announces Public Offering Of Common Shares For US$10.1 Million 28

Merus Labs Completes Private Placement Of US$0.53 Million 28

Merus Labs International Completes Private Placement For US$2.13 Million 29

Asset Transactions 30

Okana Ventures Acquires North American Product Rights For Factive From Merus Labs For Up to US$3.4 Million 30

Merus Labs International Inc-Key Competitors 32

Key Employees 33

Locations And Subsidiaries 34

Head Office 34

Other Locations & Subsidiaries 34

Recent Developments 35

Financial Announcements 35

Feb 14, 2017: Merus Labs Reports Fiscal Q1 2017 Results 35

Dec 14, 2016: Merus Labs Reports Fiscal Q4 and 2016 Results 38

Aug 15, 2016: Merus Labs Reports Fiscal Q3 2016 Results 41

May 11, 2016: Merus Labs Reports Fiscal Q2 2016 Results 44

Feb 11, 2016: Merus Labs Reports Solid Fiscal Q1 2016 Results 46

Corporate Communications 48

Jun 30, 2016: Merus Labs Appoints Two New Senior Executives 48

Other Significant Developments 49

May 04, 2017: Merus Labs Announces Key Milestone for Sintrom Profit Enhancing Initiative 49

Jul 04, 2016: Merus Announces Reduced Leverage and Provides Business Update 50

Appendix 51

Methodology 51

About GlobalData 51

Contact Us 51

Disclaimer 51

List of Figures

Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Merus Labs International Inc, Medical Devices Deals, 2011 to YTD 2017 11

List of Tables

Merus Labs International Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Merus Labs International Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Merus Labs International Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Merus Labs International Inc, Medical Devices Deals, 2011 to YTD 2017 11

Merus Labs International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

Merus Labs Acquires French Rights to Four Products from Sanofi for USD25 Million 13

Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 14

Merus Labs Acquires Rights to Salagen and Estraderm MX from Novartis Pharma for USD30 Million 15

Merus Labs Acquires Sintrom from Novartis 16

Merus Labs Completes Acquisition Of Prescription Medicine Product From Novartis 17

Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 18

Merus Labs Acquires Canadian Rights Of Vancocin From Iroko International 19

Merus Labs Raises USD21 Million in Private Placement of Shares upon Exercise of Warrants 20

Merus Labs Raises USD20 Million in Private Placement of Subscription Receipts 21

Merus Labs Completes Partial Exercise of Underwriter's Over Allotment Option for Public Offering of Shares for USD63 Million 23

Merus Labs Raises USD9.2 Million in Private Placement of Preferred Shares 24

Merus Labs Raises USD28.7 Million in Public Offering of Shares 25

Merus Labs International Completes Underwriters Exercise Of Full Over-Allotment Option Of Private Placement Of Shares For US$20.7 Million 26

Merus Labs Completes Private Placement Of Shares For US$4.4 Million 27

Merus Labs Announces Public Offering Of Common Shares For US$10.1 Million 28

Merus Labs Completes Private Placement Of US$0.53 Million 28

Merus Labs International Completes Private Placement For US$2.13 Million 29

Okana Ventures Acquires North American Product Rights For Factive From Merus Labs For Up to US$3.4 Million 30

Merus Labs International Inc, Key Competitors 32

Merus Labs International Inc, Key Employees 33

Merus Labs International Inc, Subsidiaries 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Merus Labs International Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16020
Site License
USD 500 INR 32040
Corporate User License
USD 750 INR 48060

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com